High DEPTOR expression correlates with poor prognosis in patients with esophageal squamous cell carcinoma

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 3449-3455

  Liu, Nan Bo ^a   Zhang, Jun Hua ^a   Liu, Yu Fan ^a   Li, Jun ^b   Zhang, Zhen Zhong ^a   Li, Ji Wei ^a   Liu, Wen Yue ^a   Huang, Chen ^a,c   Shen, Tao ^d   Gu, Cheng Wei ^e   Gao, Dong Yun ^f   Wu, Xia ^g   Wu, Xu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^c FUJIAN PROVINCIAL HOSPITAL   (China)

^d JIANGMEN CENTRAL HOSPITAL   (China)

^e XINXIANG MEDICAL UNIVERSITY   (China)

^f Dongtai People s Hospital   (China)

^g BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

DEPTOR; ESCC; Prognosis

Indexed keywords

BINDING PROTEIN; DISHEVELED EGL 10 AND PLECKSTRIN DOMAIN CONTAINING MAMMALIAN TARGET OF RAPAMYCIN INTERACTING PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; WESTERN BLOTTING;

EID: 84947920556     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S92862     Document Type: Article

References (20)

1. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol. 2005; 6(11): 864-870.
2. Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol. 2012; 30(4): 413-418.
3. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013; 497(7448): 217-223.
4. Souroullas GP, Sharpless NE. mTOR signaling in melanoma: oncogene-induced pseudo- senescence? Cancer Cell. 2015; 27(1): 3-5.
5. Northrup H. The mTOR inhibitor revolution rolls on. Lancet Oncol. 2014; 15(13): 1418-1419.
6. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012; 30(1): 78-84.
7. Wang Z, Zhong J, Inuzuka H, et al. An evolving role for DEPTOR in tumor development and progression. Neoplasia. 2012; 14(5): 368-375.
8. Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 2015; 25(9): 545-555.
9. Parvani JG, Davuluri G, Wendt MK, et al. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. Neoplasia. 2015; 17(3): 317-328.
10. Gentzler RD, Altman JK, Platanias LC. An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets. 2012; 16(5): 481-489.
11. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2): 274-293.
12. Altman JK, Szilard A, Goussetis DJ, et al. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res. 2014; 20(9): 2400-2409.
13. Yang Y, Bardeleben C, Frost P, et al. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer. 2014; (11-12): 407-419.
14. Bruneau S, Nakayama H, Woda CB, Flynn EA, Briscoe DM. DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood. 2013; 122(10): 1833-1842.
15. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. mTOR inhibitors in breast cancer: a systematic review. Gynecol Oncol. 2012; 127(3): 662-672.
16. Li H, Sun GY, Zhao Y, et al. DEPTOR has growth suppression activity against pancreatic cancer cells. Oncotarget. 2014; 5(24): 12811-12819.
17. Zhang HR, Chen JM, Zeng ZY, Que WZ. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res. 2013; 41(3): 584-595.
18. Corominas-Faja B, Cufí S, Oliveras-Ferraros C, et al. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle. 2013; 12(18): 3109-3124.
19. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009; 59(2): 111-137.
20. Pande M, Bondy ML, Do KA, et al. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat. 2014; 147(2): 381-387.